FDA APPROVES DRUG FOR HEMOPHILIA PATIENTS

                         Roanoke Times
                 Copyright (c) 1995, Landmark Communications, Inc.

DATE: FRIDAY, February 26, 1993                   TAG: 9302260099
SECTION: NATL/INTL                    PAGE: A10   EDITION: STATE 
SOURCE: 
DATELINE: WASHINGTON                                LENGTH: Short
FDA APPROVES DRUG FOR HEMOPHILIA PATIENTS
The first hemophilia clotting drug made by genetic engineering has been approved for marketing by the Food and Drug Administration, a Connecticut firm announced Thursday.
Miles Inc. of West Haven, Conn., said that the FDA has approved sale of a drug called Kogenate that can be used by patients with hemophilia A to prevent bleeding.
Kogenate replaces a substance called factor VIII that is missing or in short supply in the blood of patients with hemophilia A. Without the factor, the blood will not clot naturally, leading to uncontrolled bleeding.
- Associated Press
Memo: shorter version ran in the Metro edition.

by Archana Subramaniam by CNB